Immuneering (IMRX) Revenue & Revenue Breakdown
Immuneering Revenue Highlights
00
Immuneering Revenue by Period
Immuneering Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | - | 100.00% |
| 2023-12-31 | - | -100.00% |
| 2022-12-31 | $316.95K | -84.76% |
| 2021-12-31 | $2.08M | -10.02% |
| 2020-12-31 | $2.31M | 20.41% |
| 2019-12-31 | $1.92M | - |
Immuneering generated - in revenue during NA 2024, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Immuneering Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-03-31 | - | -100.00% |
| 2024-12-31 | $726.33K | 100.00% |
| 2024-09-30 | - | 100.00% |
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $-94.42M | 100.00% |
| 2023-09-30 | - | -100.00% |
| 2023-06-30 | $94.42M | 100.00% |
| 2023-03-31 | - | -100.00% |
| 2022-12-31 | $456.00 | -98.81% |
| 2022-09-30 | $38.38K | -59.35% |
| 2022-06-30 | $94.42K | -48.60% |
| 2022-03-31 | $183.70K | -3.11% |
| 2021-12-31 | $189.59K | -60.68% |
| 2021-09-30 | $482.13K | -26.95% |
| 2021-06-30 | $660.04K | -11.78% |
| 2021-03-31 | $748.20K | 12.50% |
| 2020-12-31 | $665.08K | -2.56% |
| 2020-09-30 | $682.57K | 41.96% |
| 2020-06-30 | $480.83K | -0.46% |
| 2020-03-31 | $483.05K | - |
Immuneering generated - in revenue during Q1 2025, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Immuneering Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| RXST | RxSight | $139.93M | $40.21M |
| CTKB | Cytek Biosciences | $111.11M | $57.48M |
| RPID | Rapid Micro Biosystems | $28.05M | $8.22M |
| OBIO | Orchestra BioMed | $2.64M | $868.00K |
| IMRX | Immuneering | - | - |
| TRML | Tourmaline Bio | - | - |
| NVCT | Nuvectis Pharma | - | - |
| CNTA | Centessa Pharmaceuticals | - | - |
| OLMA | Olema Pharmaceuticals | - | - |
| LRMR | Larimar Therapeutics | - | - |